Dexamethasone Associated Systemic Hypertension in Low Birth Weight Babies with Chronic Lung Disease
Overview
Authors
Affiliations
Unlabelled: To assess the role of dexamethasone treatment as a cause of systemic hypertension and associated complications, blood pressure was registered prospectively before, during and after a 4-week dexamethasone course in 22 neonates with chronic lung disease. In all patients systolic blood pressure rose significantly during treatment (median rise 34 mm Hg, range 4-->59 mm Hg), without complications attributable to hypertension. In all but one patient blood pressure returned to pretreatment values within 2 weeks after stopping dexamethasone treatment.
Conclusion: Dexamethasone induced hypertension is transient, even after a 4-week course, and is not associated with hypertensive complications, so treatment is not necessary. When hypertension persists after dexamethasone withdrawal other causes should be considered.
Pharande P, Sehgal A, Menahem S J Cardiovasc Dev Dis. 2024; 11(8).
PMID: 39195141 PMC: 11354795. DOI: 10.3390/jcdd11080233.
The effectiveness of dexamethasone as a combination therapy for COVID-19.
Namazi N Acta Pharm. 2023; 72(3):345-358.
PMID: 36651541 DOI: 10.2478/acph-2022-0030.
Neonatal hypertension: concerns within and beyond the neonatal intensive care unit.
Altemose K, Dionne J Clin Exp Pediatr. 2022; 65(8):367-376.
PMID: 35638239 PMC: 9348950. DOI: 10.3345/cep.2022.00486.
Potential Adverse Effects of Dexamethasone Therapy on COVID-19 Patients: Review and Recommendations.
Chen F, Hao L, Zhu S, Yang X, Shi W, Zheng K Infect Dis Ther. 2021; 10(4):1907-1931.
PMID: 34296386 PMC: 8298044. DOI: 10.1007/s40121-021-00500-z.
Neonatal hypertension: an educational review.
Harer M, Kent A Pediatr Nephrol. 2018; 34(6):1009-1018.
PMID: 29974208 DOI: 10.1007/s00467-018-3996-1.